BioTuesdays

Tag - William Blair

Biodesix Logo

Analysts start Biodesix at buy and OP

200 Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

Codiak-Logo

William Blair starts Codiak BioSciences at OP

William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...

Aspira-Women's-Health-Logo

William Blair starts Aspira Women’s Health at OP

William Blair launched coverage of Aspira Women’s Health (NASDAQ:AWH) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. The company’s current product line, the OVA family, is used for presurgical pelvic...

DermTech-Logo

William Blair starts DermTech at OP

William Blair initiated coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating. The stock closed at $11.75 on Oct. 29. Analyst Brian Weinstein writes that DermTech is focused on driving adoption of its non...

WB starts Aravive at OP

William Blair launched coverage of Aravive (NASDAQ:ARAV) with an “outperform” rating, saying that an “appreciable market disconnect exists between lead asset AVB-500’s potential to emerge as a differentiated therapeutic...

Neuronetics Logo

WB cuts Neuronetics to market perform

William Blair downgraded Neuronetics (NASDAQ:STIM) to “market perform,” citing added uncertainty from COVID-19 headwinds and a commercial restructuring. The stock was quoted at $2.20, down 16 cents, in afternoon trading...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.